retatrutide clinical trials sign up Retatrutide, Eli Lilly's next generation of weight loss injections, showed dramatic results in trials, with patients losing an average of to 71.2 pounds, or 28.7% of their body weight. Eli New Phase 3 retatrutide data

Retatrutide is not FDA approved, not EMA approved, and has no approved prescription pathway as of April 2026

Retatrutide, a new weight loss from Eli Lilly, isnt even out yet

Any website or vendor claiming to sell retatrutide for personal use is operating outside legal boundaries

This is the single most important point for dose-selection decisions going forward and is the reason the 9 mg arm and the new 4 mg maintenance dose are under such close scrutiny

This is the first Phase 3 GLP-1-class readout that specifically demonstrates symptomatic benefit in knee osteoarthritis beyond what would be expected from weight loss alone, and it opens the possibility, still to be confirmed in dedicated trials, that GLP-1 receptor signaling has direct anti-inflammatory or disease-modifying effects on joint tissue